Related Experiment Videos
Transient hemiparesis associated with monoclonal CD3 antibody (OKT3) therapy
J D Osterman1, D A Trauner, V M Reznik
1Department of Neurosciences, University of California School of Medicine, San Diego, USA.
Pediatric Neurology
|November 1, 1993
Abstract:
OKT3 therapy for prevention or reversal of allograft rejection has been associated with a constellation of acute systemic side effects, defined as an OKT3 first-dose reaction. Specific neurologic syndromes, including aseptic meningitis and diffuse encephalitis, have also been observed. This report describes a 12-year-old girl with steroid-resistant renal allograft rejection who developed hemiparesis associated with initiation of OKT3 therapy.